Search Within

Andrea D. Basso

Formats
  1. Meeting Abstract (19)
  2. Journal Article (13)
Groups
  1. Department of Medicine (32)
  2. GSK Faculty (32)
  3. Solid Tumor Oncology Division (32)
  4. Breast Medicine Service (31)
  5. Molecular Pharmacology and Chemistry Program Faculty (31)
  6. Sloan Kettering Institute Faculty (31)

More Groups

People
  1. Neal Rosen (31)
  2. David Solit (25)
  3. Pamela Munster (7)
  4. Howard Scher (6)
  5. Mark Moasser (6)
  6. Olivera Grbovic-Huezo (6)

More People

Years
  1. 2006 (2)
  2. 2005 (3)
  3. 2004 (3)
  4. 2003 (9)
  5. 2002 (7)
  6. 2001 (6)

More Years

Publications
  1. Clinical Cancer Research (9)
  2. Cancer Research (8)
  3. Proceedings of the American Association for Cancer Research Annual Meeting (6)
  4. Oncogene (2)
  5. Breast Cancer Research and Treatment (1)
  6. Chemistry and Biology (1)

More Publications

Publishers
  1. American Association for Cancer Research (23)
  2. Nature Publishing Group (3)
  3. Elsevier Inc. (2)
  4. American Society for Biochemistry and Molecular Biology (1)
  5. Bentham Science Publishers (1)
  6. National Academy of Sciences (1)

More Publishers

Results (32)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cyclin D expression and G1 progression are dependent on MEK-MAP kinase activity in tumor cells with B-Raf mutation but not in breast cancer cells with wild type Ras
    Meeting Abstract

    Sawai, A.; Basso, A. D.; Solit, D. B.; She, Q. B.; Grbovic, O.; Pratilas, C.; Chapman, P.; Moasser, M. M.; Rosen, N.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Activated, mutated B-Raf protein kinase requires the Hsp90 chaperone protein for folding and stability and is degraded in response to Hsp90 inhibitors
    Meeting Abstract

    Grbovic, O. M.; Basso, A. D.; Houghton, A.; Solit, D. B.; Rosen, N.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Development of purine-scaffold small molecule inhibitors of Hsp90
    Journal Article

    Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N.
    Current Cancer Drug Targets (2003)

    Fulltext@MSK | Save
  • The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells
    Journal Article

    Xu, W.; Yuan, X.; Jung, Y. J.; Yang, Y.; Basso, A.; Rosen, N.; Chung, E. J.; Trepel, J.; Neckers, L.
    Cancer Research (2003)

    Fulltext@MSK | Save
  • Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
    Journal Article

    Solit, D. B.; Basso, A. D.; Olshen, A. B.; Scher, H. I.; Rosen, N.
    Cancer Research (2003)

    Fulltext@MSK | Save
  • Resistance to gefitinib in PTEN-Null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling
    Journal Article

    She, Q. B.; Solit, D.; Basso, A.; Moasser, M. M.
    Clinical Cancer Research (2003)

    Fulltext@MSK | Save
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors
    Journal Article

    Bianco, R.; Shin, I.; Ritter, C. A.; Yakes, F. M.; Basso, A.; Rosen, N.; Tsurutani, J.; Dennis, P. A.; Mills, G. B.; Arteaga, C. L.
    Oncogene (2003)

    Fulltext@MSK | Save
  • Identification and synthesis of novel small molecules that bind to and modulate Hsp90 function
    Meeting Abstract

    Solit, D. B.; Basso, A.; Huezo, H.; Shtil, A.; Rosen, N.; Chiosis, G.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • The Akt protein kinase is a direct target of ansamycin antibiotics
    Meeting Abstract

    Basso, A. D.; Solit, D.; Rosen, N.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • Inhibition of the PI3 kinase/Akt pathway mediates the antitumor effects of ZD1839 (Iressa) in HER2-overexpressing tumors
    Meeting Abstract

    Basso, A.; Averbuch, S. D.; Rosen, N.; Moasser, M. M.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save